BioSpace News Archive

D2 Consulting, a leading life sciences consulting firm offering strategic and tactical commercialization services to pharmaceutical, biotechnology, medical device and digital health manufacturers, announces its acquisition of WorkUp, Inc., a unique patient engagement solution that improves operational efficiencies and enhances patient outcomes related to the care of complex specialty patients.

One year since launch, several new partners and health care offerings have been added to Walgreens Find Care

Formed in early 2006, Delaware BioScience Association (Delaware Bio) has brought together pharmaceutical and biotechnology firms, medical device manufacturers, agricultural biotech and chemical companies, research and testing companies, hospitals and medical institutions, and other organizations and related service companies, with the shared goal of expanding our state’s vibrant science economy

Emmaus Life Sciences, Inc. (Nasdaq: EMMA), announced today that it received a notice (the “Notice”) from the Listing Qualifications Staff of The Nasdaq Stock Market

Chemotherapy and radiation target cancer cells but these treatments produce unwanted side effects on healthy tissue.

The U.S. Food and Drug Administration announced it has recently suspended the food facility registration of Topway Enterprises Inc., also doing business as Kazy’s Gourmet, of Houston, Texas.

Innovative TEMPO instrument will measure major air pollutants over North America at each hour of the day

Plasmid CMO VGXI, Inc. and Geneos Therapeutics, Inc., a spin-out of Inovio Pharmaceuticals (NASDAQ: INO) focused on developing DNA-based, Neoantigen-targeting personalized cancer immunotherapies, announced today they have entered into a long-term master supply agreement.

Samsung has announced iQuia™, a new digital radiography (DR) platform of premium products and technologies that improves the healthcare experience in clinical daily practices through innovations in quality, imaging, and applications.

Manhattan Scientifics (OTC: QB MHTX) clarifies that it continues to own 64 million shares of Imagion Biosystems Ltd (ASX: IBX)